Pharmacist support 24/7

Skyrizi Risankizumab Crohns Disease Ulcerative Colitis IBD 2026

Author: Critical Kare PharmaIBD & Advanced Biologics Desk

On November 14, 2026, European and North American gastroenterology congresses highlighted the established therapeutic supremacy of Skyrizi® (Risankizumab-rzaa 600 mg IV vial and 180 mg/360 mg on-body subcutaneous injectors) by AbbVie across both Crohn's disease and ulcerative colitis.

By exclusively targeting the p19 subunit of interleukin-23 with high affinity, Skyrizi achieves profound endoscopic healing and long-term histological-endoscopic mucosal remission while demonstrating an exemplary infection safety profile compared to older anti-TNF and JAK inhibitor classes.

Through Critical Kare Pharma, authentic manufacturer packs of Skyrizi Risankizumab IV and On-Body Subcutaneous Injectors are delivered worldwide under 2°C–8°C cold-chain surveillance.

Skyrizi Risankizumab on-body injector and IV infusion vials in sterile clinical dispensary

Landmark ADVANCE, MOTIVATE & COMMAND Trial Data

  • Endoscopic Response in Crohn's Disease: Over 40% of patients achieved endoscopic response at Week 12 following three 600 mg IV induction doses, maintaining steroid-free clinical remission through 52 weeks on 360 mg subcutaneous on-body delivery every 8 weeks.
  • Ulcerative Colitis Success: In the COMMAND maintenance trial, 31% of risankizumab-treated UC patients achieved complete clinical remission and 40% attained endoscopic improvement at one year.
  • Histological Healing: High rates of complete crypt architecture restoration and mucosal healing, translating to reduced hospitalizations and bowel resection surgeries.

Targeted IL-23p19 Pharmacology

Risankizumab blocks IL-23 without cross-reacting with IL-12, thereby extinguishing the chronic pathogenic IL-17/IL-22 inflammatory axis driven by Th17 lymphocytes without impairing Th1-mediated antimicrobial surveillance. This selective mechanism explains why opportunistic infection rates remain near background placebo levels.

International Sourcing & Logistics

Critical Kare Pharma ensures temperature-validated transport from Europe and North America directly to gastroenterology hospitals, infusion suites, and named patients globally.

Specialty Medicines

Skyrizi Risankizumab Crohns Disease Ulcerative Colitis IBD 2026

C
Critical Kare PharmaIBD & Advanced Biologics Desk
November 14, 2026—
Skyrizi Risankizumab Crohns Disease Ulcerative Colitis IBD 2026
Critical Kare

At a glance

Evidence-informed overview from Critical Kare Pharma. Key themes in this article:

  • Clinically reviewed framing
  • Safety & protocol awareness
  • Patient-relevant takeaways

Prefer to chat on WhatsApp?

Message our pharmacy team directly about this treatment — we reply with product details, sourcing, and next steps.

Chat on WhatsApp

On November 14, 2026, European and North American gastroenterology congresses highlighted the established therapeutic supremacy of Skyrizi® (Risankizumab-rzaa 600 mg IV vial and 180 mg/360 mg on-body subcutaneous injectors) by AbbVie across both Crohn's disease and ulcerative colitis.

By exclusively targeting the p19 subunit of interleukin-23 with high affinity, Skyrizi achieves profound endoscopic healing and long-term histological-endoscopic mucosal remission while demonstrating an exemplary infection safety profile compared to older anti-TNF and JAK inhibitor classes.

Through Critical Kare Pharma, authentic manufacturer packs of Skyrizi Risankizumab IV and On-Body Subcutaneous Injectors are delivered worldwide under 2°C–8°C cold-chain surveillance.

Skyrizi Risankizumab on-body injector and IV infusion vials in sterile clinical dispensary

Landmark ADVANCE, MOTIVATE & COMMAND Trial Data

  • Endoscopic Response in Crohn's Disease: Over 40% of patients achieved endoscopic response at Week 12 following three 600 mg IV induction doses, maintaining steroid-free clinical remission through 52 weeks on 360 mg subcutaneous on-body delivery every 8 weeks.
  • Ulcerative Colitis Success: In the COMMAND maintenance trial, 31% of risankizumab-treated UC patients achieved complete clinical remission and 40% attained endoscopic improvement at one year.
  • Histological Healing: High rates of complete crypt architecture restoration and mucosal healing, translating to reduced hospitalizations and bowel resection surgeries.

Targeted IL-23p19 Pharmacology

Risankizumab blocks IL-23 without cross-reacting with IL-12, thereby extinguishing the chronic pathogenic IL-17/IL-22 inflammatory axis driven by Th17 lymphocytes without impairing Th1-mediated antimicrobial surveillance. This selective mechanism explains why opportunistic infection rates remain near background placebo levels.

International Sourcing & Logistics

Critical Kare Pharma ensures temperature-validated transport from Europe and North America directly to gastroenterology hospitals, infusion suites, and named patients globally.


C

Critical Kare PharmaIBD & Advanced Biologics Desk

Specialists in selective IL-23 inhibition, mucosal healing biomarkers, gastroenterology biologics, and cold-chain pharmaceutical shipping.

Continue your care journey

This article is for general education. For medicine availability, prescriptions, and orders, use our catalog and pharmacy team.

Chat on WhatsAppBrowse catalogTreatmentsContact pharmacistsUpload prescription

Related Articles

Omvoh Mirikizumab IL23p19 Ulcerative Colitis Remission 2026

Specialty Medicines

Omvoh Mirikizumab IL23p19 Ulcerative Colitis Remission 2026

Read Article

Found this helpful?